This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
by Zacks Equity Research
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
RHHBYNegative Net Change JNJNegative Net Change PFEPositive Net Change PTGXPositive Net Change
biotechs medical pharmaceuticals
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
by Zacks Equity Research
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
AZNNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
ADCTPositive Net Change ZTSNegative Net Change ALLONegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change
biotechnology biotechs gene-therapy pharmaceuticals
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
by Ekta Bagri
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
NVSNegative Net Change BMYNo Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is J&J's MedTech Segment Set for Another Quarter of Growth?
by Kinjel Shah
J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.
BSXNegative Net Change JNJNegative Net Change MDTNegative Net Change SYKNegative Net Change
pharmaceuticals
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
by Shaun Pruitt
With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary
JNJNegative Net Change GILDPositive Net Change KRNegative Net Change
dividend-investing dividends investing medical pharmaceuticals retail
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
by Kinjel Shah
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
JNJNegative Net Change AMGNNegative Net Change TEVANegative Net Change KVUENegative Net Change
pharmaceuticals
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
by Kanishka Das
MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
AZNNegative Net Change RHHBYNegative Net Change BMYNo Net Change MRKPositive Net Change
pharmaceuticals
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
by Zacks Equity Research
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
OVIDPositive Net Change ALLONegative Net Change AKROPositive Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
by Ahan Chakraborty
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for October 10th
by Zacks Equity Research
EGAN, MDB, INVA, LIF and PGR have been added to the Zacks Rank #1 (Strong Buy) List on October 10th, 2025.
PGRNegative Net Change EGANNegative Net Change INVANegative Net Change MDBPositive Net Change LIFPositive Net Change
computers industrial-products insurance pharmaceuticals
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers
by Zacks Equity Research
Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.
JNJNegative Net Change BAYRYPositive Net Change ANIPNegative Net Change EXASNegative Net Change
pharmaceuticals
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
by Kinjel Shah
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
by Zacks Equity Research
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
NVSNegative Net Change PMNegative Net Change SAPNegative Net Change CLRONegative Net Change ICCCPositive Net Change
communications computers consumer-staples medical pharmaceuticals
Top Stock Reports for SAP, Novartis & Philip Morris
by Mark Vickery
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
NVSNegative Net Change PMNegative Net Change SAPNegative Net Change CLRONegative Net Change ICCCPositive Net Change UBERNegative Net Change NETPositive Net Change HOODPositive Net Change
communications computers consumer-staples medical pharmaceuticals
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
JNJNegative Net Change BAYRYPositive Net Change FOLDPositive Net Change SPROPositive Net Change
biotechnology biotechs medical pharmaceuticals
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
KALAPositive Net Change ALLONegative Net Change AKROPositive Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
by Zacks Equity Research
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
BIIBNegative Net Change BMYNo Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
by Kinjel Shah
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
AZNNegative Net Change BMYNo Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
by Kinjel Shah
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
NVSNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change BAYRYPositive Net Change
pharmaceuticals
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
by Zacks Equity Research
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
PFEPositive Net Change AMGNNegative Net Change GDRXPositive Net Change
biotechs medical pharmaceuticals
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
by Zacks Equity Research
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
MRKPositive Net Change ALLONegative Net Change AKROPositive Net Change CMMBPositive Net Change
pharmaceuticals